vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Paylocity Holding Corp (PCTY). Click either name above to swap in a different company.
Paylocity Holding Corp is the larger business by last-quarter revenue ($387.0M vs $281.3M, roughly 1.4× Guardant Health, Inc.). Paylocity Holding Corp runs the higher net margin — 13.0% vs -45.7%, a 58.7% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 11.3%). Paylocity Holding Corp produced more free cash flow last quarter ($113.6M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 2.7%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Paylocity Holding Corporation is an American provider of cloud-based payroll, , spend management, and human capital management (HCM) software.
GH vs PCTY — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $387.0M |
| Net Profit | $-128.5M | $50.2M |
| Gross Margin | 64.6% | 72.9% |
| Operating Margin | -43.0% | 18.2% |
| Net Margin | -45.7% | 13.0% |
| Revenue YoY | 39.4% | 11.3% |
| Net Profit YoY | -15.8% | 34.0% |
| EPS (diluted) | $-1.01 | $0.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $387.0M | ||
| Q3 25 | $265.2M | $378.9M | ||
| Q2 25 | $232.1M | $369.9M | ||
| Q1 25 | $203.5M | $421.1M | ||
| Q4 24 | $201.8M | $347.7M | ||
| Q3 24 | $191.5M | $333.1M | ||
| Q2 24 | $177.2M | $324.7M | ||
| Q1 24 | $168.5M | $366.8M |
| Q4 25 | $-128.5M | $50.2M | ||
| Q3 25 | $-92.7M | $48.0M | ||
| Q2 25 | $-99.9M | $48.6M | ||
| Q1 25 | $-95.2M | $91.5M | ||
| Q4 24 | $-111.0M | $37.5M | ||
| Q3 24 | $-107.8M | $49.6M | ||
| Q2 24 | $-102.6M | $48.8M | ||
| Q1 24 | $-115.0M | $85.3M |
| Q4 25 | 64.6% | 72.9% | ||
| Q3 25 | 64.7% | 73.9% | ||
| Q2 25 | 65.0% | 73.5% | ||
| Q1 25 | 63.3% | 77.1% | ||
| Q4 24 | 61.6% | 72.6% | ||
| Q3 24 | 61.1% | 74.4% | ||
| Q2 24 | 59.1% | 74.0% | ||
| Q1 24 | 61.2% | 77.8% |
| Q4 25 | -43.0% | 18.2% | ||
| Q3 25 | -37.3% | 19.6% | ||
| Q2 25 | -45.9% | 17.9% | ||
| Q1 25 | -54.6% | 30.2% | ||
| Q4 24 | -62.4% | 13.4% | ||
| Q3 24 | -61.3% | 19.3% | ||
| Q2 24 | -56.8% | 19.4% | ||
| Q1 24 | -59.2% | 29.0% |
| Q4 25 | -45.7% | 13.0% | ||
| Q3 25 | -35.0% | 12.7% | ||
| Q2 25 | -43.0% | 13.1% | ||
| Q1 25 | -46.8% | 21.7% | ||
| Q4 24 | -55.0% | 10.8% | ||
| Q3 24 | -56.3% | 14.9% | ||
| Q2 24 | -57.9% | 15.0% | ||
| Q1 24 | -68.2% | 23.3% |
| Q4 25 | $-1.01 | $0.92 | ||
| Q3 25 | $-0.74 | $0.86 | ||
| Q2 25 | $-0.80 | $0.87 | ||
| Q1 25 | $-0.77 | $1.61 | ||
| Q4 24 | $-0.90 | $0.66 | ||
| Q3 24 | $-0.88 | $0.88 | ||
| Q2 24 | $-0.84 | $0.85 | ||
| Q1 24 | $-0.94 | $1.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $162.5M |
| Total DebtLower is stronger | $1.5B | $81.3M |
| Stockholders' EquityBook value | $-99.3M | $1.1B |
| Total Assets | $2.0B | $7.0B |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $162.5M | ||
| Q3 25 | $580.0M | $165.2M | ||
| Q2 25 | $629.1M | $398.1M | ||
| Q1 25 | $698.6M | $477.8M | ||
| Q4 24 | $525.5M | $482.4M | ||
| Q3 24 | $585.0M | $778.5M | ||
| Q2 24 | $933.7M | $401.8M | ||
| Q1 24 | $1.0B | $492.7M |
| Q4 25 | $1.5B | $81.3M | ||
| Q3 25 | $1.1B | $81.3M | ||
| Q2 25 | $1.1B | $162.5M | ||
| Q1 25 | $1.1B | $243.8M | ||
| Q4 24 | $1.1B | $325.0M | ||
| Q3 24 | — | $325.0M | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $1.1B | ||
| Q3 25 | $-354.5M | $1.1B | ||
| Q2 25 | $-305.5M | $1.2B | ||
| Q1 25 | $-250.8M | $1.2B | ||
| Q4 24 | $-139.6M | $1.2B | ||
| Q3 24 | $-60.1M | $1.1B | ||
| Q2 24 | $-1.6M | $1.0B | ||
| Q1 24 | $68.3M | $1.1B |
| Q4 25 | $2.0B | $7.0B | ||
| Q3 25 | $1.3B | $4.2B | ||
| Q2 25 | $1.3B | $4.4B | ||
| Q1 25 | $1.3B | $5.2B | ||
| Q4 24 | $1.5B | $5.3B | ||
| Q3 24 | $1.5B | $4.0B | ||
| Q2 24 | $1.6B | $4.2B | ||
| Q1 24 | $1.7B | $5.0B |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.20× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | 0.29× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $117.0M |
| Free Cash FlowOCF − Capex | $-54.2M | $113.6M |
| FCF MarginFCF / Revenue | -19.3% | 29.4% |
| Capex IntensityCapex / Revenue | 9.9% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 2.33× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $461.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $117.0M | ||
| Q3 25 | $-35.4M | $86.5M | ||
| Q2 25 | $-60.3M | $86.6M | ||
| Q1 25 | $-62.7M | $186.0M | ||
| Q4 24 | $-64.5M | $54.2M | ||
| Q3 24 | $-51.1M | $91.5M | ||
| Q2 24 | $-94.0M | $79.9M | ||
| Q1 24 | $-30.3M | $167.5M |
| Q4 25 | $-54.2M | $113.6M | ||
| Q3 25 | $-45.8M | $82.7M | ||
| Q2 25 | $-65.9M | $81.1M | ||
| Q1 25 | $-67.1M | $183.7M | ||
| Q4 24 | $-83.4M | $51.2M | ||
| Q3 24 | $-55.3M | $89.1M | ||
| Q2 24 | $-99.1M | $73.6M | ||
| Q1 24 | $-37.2M | $162.0M |
| Q4 25 | -19.3% | 29.4% | ||
| Q3 25 | -17.3% | 21.8% | ||
| Q2 25 | -28.4% | 21.9% | ||
| Q1 25 | -33.0% | 43.6% | ||
| Q4 24 | -41.3% | 14.7% | ||
| Q3 24 | -28.9% | 26.8% | ||
| Q2 24 | -55.9% | 22.7% | ||
| Q1 24 | -22.1% | 44.2% |
| Q4 25 | 9.9% | 0.9% | ||
| Q3 25 | 3.9% | 1.0% | ||
| Q2 25 | 2.4% | 1.5% | ||
| Q1 25 | 2.2% | 0.5% | ||
| Q4 24 | 9.4% | 0.9% | ||
| Q3 24 | 2.2% | 0.7% | ||
| Q2 24 | 2.9% | 1.9% | ||
| Q1 24 | 4.1% | 1.5% |
| Q4 25 | — | 2.33× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 1.78× | ||
| Q1 25 | — | 2.03× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | 1.84× | ||
| Q2 24 | — | 1.64× | ||
| Q1 24 | — | 1.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PCTY
| Recurring Fees | $370.1M | 96% |
| Implementation Services And Other | $16.9M | 4% |
